Buscar
InflaRx NV
IFRXAñadir a la lista de seguimiento
2.090USD
-0.080-3.69%
Cierre 09-09 16:00（ET）
308.00MCap. mercado
PérdidaP/E TTM
Más Datos de InflaRx NV Compañía
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Perfil de InflaRx NV
Símbolo de cotizaciónIFRX
Nombre de la empresaInflaRx NV
Fecha de salida a bolsaNov 08, 2017
Director ejecutivoRiedemann (Niels C)
Número de empleados74
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 08
DirecciónWinzerlaer Str. 2
CiudadJENA
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísGermany
Código postal07745
Teléfono493641508180
Sitio Webhttps://www.inflarx.de/
Símbolo de cotizaciónIFRX
Fecha de salida a bolsaNov 08, 2017
Director ejecutivoRiedemann (Niels C)
Ejecutivos de InflaRx NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D.
Prof. Niels C. Riedemann, M.D., Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D.
Prof. Niels C. Riedemann, M.D., Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de InflaRx NV?
Los cinco principales accionistas de InflaRx NV son: Mr. Nicolas Fulpius
¿Cuántas instituciones poseen acciones de InflaRx NV (IFRX)?
A fecha de 2026Q1, 82 instituciones poseen acciones de InflaRx NV, con un valor de mercado combinado de aproximadamente 19.59M, lo que representa el 13.30% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -4596250.00.